NR2F2 and neoplasm: Based on the above‐mentioned evidence and some preliminary experiments, we hypothesized that NR2F2‐AS1 could suppress the epithelial‐mesenchymal transition (EMT), migration, invasion of OSCC cells, and angiogenesis of human umbilical vein endothelial cells (HUVECs) and attenuate tumor growth and metastasis of OSCC in vivo through the miR‐32‐5p/SEMA3A axis.